Biomea Fusion Inc. has prepared new fused pyrimidine compounds acting as menin (MEN1)/KMT2A (MLL) interaction inhibitors. They are reported to be potentially useful for the treatment of cancer, osteoporosis, autoimmune diseases, inflammatory diseases, type 1 and 2 diabetes.